Cancer
Scientists at Sichuan University in the People's Republic of China have discovered that microRNA-204-5p functions as a tumor suppressor in gastric cancer by inhibiting cell migration, invasion, and glycolysis. The research, published in Scientific Reports, found that miRNA-204-5p targets RAB22A and inhibits the PI3K/AKT signaling pathway, leading
Cancer
Researchers from the Department of Ultrasound at The First Affiliated Hospital of Harbin Medical University have made a groundbreaking discovery in cancer treatment. By combining two forms of regulated cell death, apoptosis and ferroptosis, their innovative microneedle patch system has shown significant promise in overcoming chemoresistance and improving breast cancer
Cancer
A groundbreaking study published in the journal Drug Development Research has uncovered the crucial role of the MYB/IQGAP3 axis in mediating 5-Fluorouracil (5-FU) resistance in gastric cancer (GC) cells. The research, led by Piyao Gao and colleagues from Ruikang Hospital Affiliated to Guangxi University of Traditional Chinese Medicine, reveals
Cancer
Researchers at Lanzhou University have developed a CT radiomics model that can predict microsatellite instability (MSI) status and immunotherapy response in gastric cancer patients. The model demonstrates good predictive performance, achieving AUCs of 0.952, 0.835, and 0.879 in the training set and two external testing sets, respectively.
Cancer
Recent research has shed new light on the crucial role of coagulation factor family genes in gastric cancer progression and immune evasion. Conducted by a team of researchers from Lanzhou University, the study utilized single-cell and The Cancer Genome Atlas datasets to investigate the clinical and immune relevance of coagulation
Cancer
A Bournemouth family-run business, Pro Drainage Group, has successfully hosted a charity fundraiser to celebrate their decade in business, raising £10,000 for Macmillan Cancer Support. The event, attended by over 90 local businesses, featured a raffle, and contributions to a JustGiving page, exceeding the fundraising target. The business'
Cancer
Researchers from China National Nuclear Corporation 416 Hospital in Chengdu, China, have developed an innovative oral probiotic, K12@Lip@GSH, to overcome the challenges of radiation-induced oral mucositis (RIOM) in patients with head and neck cancer undergoing radiotherapy or chemotherapy. This groundbreaking approach encapsulates K12 within liposomes to enhance stability
Cancer
Research from Technical University Munich has identified heat shock protein 70 (Hsp70) as a potential biomarker for thoracic cancer, particularly for lymph node metastases and early relapse. According to the study published in BMC Cancer, Hsp70 is overexpressed in many cancer types and is present on the plasma membrane of
Cancer
Research conducted by the University of Bologna, Italy, has identified a significant correlation between the loss of human leukocyte antigen class I (HLA-I) expression and poor prognosis in endometrial cancers, particularly in the no specific molecular profile (NSMP) subtype. The study, published in the journal Histopathology, assessed HLA-I expression in
Cancer
A recent investigation has published a report on the efficacy and challenges of CAR T-cell immunotherapy in cancer treatment. According to the research, published in the journal Medical Oncology, CAR T-cell therapy has shown significant clinical benefits, particularly in hematologic malignancies. The therapy involves genetically reprogramming autologous T-cells to express
Cancer
Researchers at The Institute of Cancer Research, London, have discovered that combining a cancer-killing reovirus with targeted cancer drugs can significantly enhance immune responses and tumour destruction in lab-grown cells and mice. This groundbreaking study has the potential to revolutionize cancer treatment, offering a promising route to more effective and
Cancer
PDS Biotechnology Corporation, a late-stage immunotherapy company, has announced final topline survival data from its Phase 2 clinical trial, VERSATILE-002. The trial evaluated the safety and efficacy of PDS0101 (Versamune(R) HPV) in combination with pembrolizumab for patients with HPV16-positive first-line recurrent and/or metastatic head and neck squamous cell
